A major strength of this study is the large number of patients of races and ethnicities other than White included from diverse practice locations, allowing us to observe that tumor biologic factors and nature of disease (eg, tumor grade and ERBB2/CEP17 ratio) contributed a significant portion of the differential response to NACT by race and ethnicity. The gene discussed is ERBB2; the disease is neoplasm.